PMID- 31354475
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 10
DP  - 2019
TI  - Anti-Cancer Effects of Pristimerin and the Mechanisms: A Critical Review.
PG  - 746
LID - 10.3389/fphar.2019.00746 [doi]
LID - 746
AB  - As a quinonemethide triterpenoid extracted from species of the Celastraceae and 
      Hippocrateaceae, pristimerin has been shown potent anti-cancer effects. 
      Specifically, it was found that pristimerin can affect many tumor-related 
      processes, such as apoptosis, autophagy, migration and invasion, vasculogenesis, 
      and drug resistance. Various molecular targets or signaling pathways are also 
      involved, such as cyclins, reactive oxygen species (ROS), microRNA, nuclear 
      factor kappa B (NF-kappaB), mitogen-activated protein kinase (MAPK), and 
      PI3K/AKT/mammalian target of rapamycin (mTOR) pathways. In this review, we will 
      focus on the research about pristimerin-induced anti-cancer activities to achieve 
      a deeper understanding of the targets and mechanisms, which offer evidences 
      suggesting that pristimerin can be a potent anti-cancer drug.
FAU - Li, Jia-Jun
AU  - Li JJ
AD  - Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, 
      School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou 
      Medical University, Guangzhou, China.
FAU - Yan, Yan-Yan
AU  - Yan YY
AD  - Institute of Respiratory and Occupational Diseases, Collaborative Innovation 
      Center for Cancer, Medical College, Shanxi Datong University, Datong, China.
AD  - School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
FAU - Sun, Hong-Mei
AU  - Sun HM
AD  - Infinitus (China) Company Ltd., Jiangmen, China.
FAU - Liu, Yun
AU  - Liu Y
AD  - Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, 
      School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou 
      Medical University, Guangzhou, China.
FAU - Su, Chao-Yue
AU  - Su CY
AD  - Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, 
      School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou 
      Medical University, Guangzhou, China.
FAU - Chen, Hu-Biao
AU  - Chen HB
AD  - School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
FAU - Zhang, Jian-Ye
AU  - Zhang JY
AD  - Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, 
      School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou 
      Medical University, Guangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190712
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC6640652
OTO - NOTNLM
OT  - anti-cancer
OT  - apoptosis
OT  - autophagy
OT  - mechanism
OT  - molecular target
OT  - pharmaceutical effect
OT  - pristimerin
EDAT- 2019/07/30 06:00
MHDA- 2019/07/30 06:01
PMCR- 2019/07/12
CRDT- 2019/07/30 06:00
PHST- 2019/01/26 00:00 [received]
PHST- 2019/06/11 00:00 [accepted]
PHST- 2019/07/30 06:00 [entrez]
PHST- 2019/07/30 06:00 [pubmed]
PHST- 2019/07/30 06:01 [medline]
PHST- 2019/07/12 00:00 [pmc-release]
AID - 10.3389/fphar.2019.00746 [doi]
PST - epublish
SO  - Front Pharmacol. 2019 Jul 12;10:746. doi: 10.3389/fphar.2019.00746. eCollection 
      2019.